Targeting a specific amino acid transporter to treat lung fibrosis
Targeting the Amino Acid Transporter SLC7A5 for Treatment of Pulmonary Fibrosis
This study is looking at how a specific protein called SLC7A5 affects lung scarring in people with Idiopathic Pulmonary Fibrosis (IPF), with the hope of finding new treatments that could help improve lung function and quality of life for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11059394 on NIH RePORTER |
What this research studies
This research investigates the role of the amino acid transporter SLC7A5 in the progression of Idiopathic Pulmonary Fibrosis (IPF), a severe lung disease. The study aims to understand how SLC7A5 influences the behavior of fibroblasts, which are cells that contribute to lung scarring. By exploring the mechanisms of amino acid transport and its effects on cell signaling pathways, the research seeks to identify new therapeutic strategies that could slow down or reverse fibrosis. Patients may benefit from potential new treatments that target this transporter to improve lung function and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are experiencing rapid disease progression.
Not a fit: Patients with other forms of lung disease or those who do not have a diagnosis of pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve outcomes for patients with pulmonary fibrosis.
How similar studies have performed: While targeting amino acid transporters is a novel approach in the context of pulmonary fibrosis, similar strategies have shown promise in other fibrotic diseases.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Choudhury, Malay — Washington University
- Study coordinator: Choudhury, Malay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.